Literature DB >> 3445826

Suppression of in vitro peripheral blood lymphocyte mitogenesis by cytotoxic drugs commonly used in the treatment of breast cancer: a comparative study.

M Gereis1, A P Burford-Mason, S M Watkins.   

Abstract

Cultures of normal donor peripheral blood mononuclear cells were tested in vitro for suppression by chemotherapeutic agents or their metabolites. The drugs tested were those commonly used in the treatment of breast cancer, namely, 5-fluorouracil, doxorubicin, vincristine, methotrexate and cyclophosphamide (actually testing its active metabolite, 4-hydroxy-cyclophosphamide). The lymphocytes were stimulated by phytohaemagglutinin (PHA), and the inhibitory effect of the drugs on subsequent DNA synthesis was measured by tritiated thymidine uptake. Drug concentrations used were equivalent to expected in vivo plasma and body fluid levels following i.v. injection of a standard therapeutic dose. Results suggest that the drugs may be ranked for suppression of T-cell function as follows: doxorubicin greater than vincristine = cyclophosphamide greater than 5-fluorouracil greater than methotrexate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3445826     DOI: 10.1007/BF02009063

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  36 in total

1.  Cancer prognosis predicted by preoperative lymphocyte responsiveness in vitro.

Authors:  S M Watkins
Journal:  Br J Surg       Date:  1976-06       Impact factor: 6.939

2.  The pharmacokinetics of [3H]-vincristine in man.

Authors:  R A Bender; M C Castle; D A Margileth; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1977-10       Impact factor: 6.875

Review 3.  Immunologic aspects of cancer chemotherapy.

Authors:  C M Haskell
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

4.  The prognostic significance of DHS skin tests in patients with carcinoma of bronchus.

Authors:  H M Anthony; G H Templeman; K E Madsen; M K Mason
Journal:  Cancer       Date:  1974-12       Impact factor: 6.860

5.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

6.  Controversies in the medical management of breast cancer.

Authors:  I E Smith
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

7.  A comparison of the chemosensitivity of murine tumours in vivo and in cell culture.

Authors:  B R Bullen; C W Russell; G R Giles
Journal:  Clin Oncol       Date:  1978-09

8.  Immunologic evaluation of patients with advanced head and neck cancer receiving weekly chemoimmunotherapy.

Authors:  J Zighelboim; F Dorey; N H Parker; T Calcaterra; P Ward; J L Fahey
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

9.  Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.

Authors:  E Piazza; M G Donelli; M Broggini; C Sessa; N Natale; L Ottolenghi; S Marsoni; A Libretti; C Mangioni; L Morasca
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

10.  [Immune reactions in breast cancer patients (author's transl)].

Authors:  S I Sergejew; W W Gorodilowa; A P Baschenowa; E W Mandrik; I W Kasjanow
Journal:  Arch Geschwulstforsch       Date:  1977
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.